 Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. NASDAQ: MEIP filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharmas drug candidates is Pracinostat, an oral histone deacetylase HDAC inhibitor. 